Testing effectiveness (Phase 2)Active Not RecruitingNCT06120140
What this trial is testing
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 305